Q9JJP2
SS
Gene name |
Tp73 (P73, Trp73) |
Protein name |
Tumor protein p73 |
Names |
p53-like transcription factor , p53-related protein |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:22062 |
EC number |
|
Protein Class |
|
Descriptions
TAp63, the longest isoform of p63, is highly expressed in primary oocytes that are arrested in prophase of meiosis I. Autoinhibition of TAp63 is characterized by a reduction in affinity to DNA and activators such as p300. The transactivation (TA) domain configuration in TAp63 suppresses interaction with the acetyltransferase p300 by blocking the tetramerization interface of the tetramerization domain. This autoinhibition mechanism keeps TAp63 in a dimeric conformation, which significantly reduces its transcriptional activity compared to other forms. The proteolytic cleavage of TAp63 at either the C-terminus of the TA domain (66-67) or the N-terminus of the TI domain (591-592) results in a rapid conversion of the closed dimeric state into an open tetrameric conformation. In contrast, cleavage at the C-terminus of TAp63ɑ does not affect on the relief of autoinhibition. The detection of DNA damage initiates a kinase cascade that leads to sequential phosphorylation by Chk2 and CK1. This process results in the formation of an open and tetrameric state, which exhibits higher DNA binding affinity compared with the closed dimeric conformation.
Autoinhibitory domains (AIDs)
Target domain |
526-631 (Tetramerization domain) |
Relief mechanism |
PTM, Cleavage, Others |
Assay |
|
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q9JJP2
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q9JJP2-F1 | Predicted | AlphaFoldDB |
27 variants for Q9JJP2
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs252020949 | 4 | T>S | No | EVA | |
| rs3388735051 | 10 | S>Y | No | EVA | |
| rs3394834778 | 16 | W>R | No | EVA | |
| rs3388731120 | 20 | E>* | No | EVA | |
| rs3388741695 | 80 | E>Q | No | EVA | |
| rs3388743296 | 154 | Q>K | No | EVA | |
| rs3395183377 | 168 | R>W | No | EVA | |
| rs3388720990 | 184 | K>M | No | EVA | |
| rs3395274018 | 263 | I>N | No | EVA | |
| rs3388738808 | 282 | F>I | No | EVA | |
| rs3388741664 | 321 | A>V | No | EVA | |
| rs3388738323 | 324 | Q>L | No | EVA | |
| rs3388735101 | 353 | G>D | No | EVA | |
| rs3388738762 | 378 | V>A | No | EVA | |
| rs3388734047 | 382 | R>* | No | EVA | |
| rs3388743305 | 390 | L>I | No | EVA | |
| rs3388737632 | 449 | S>G | No | EVA | |
| rs3388734110 | 450 | H>Y | No | EVA | |
| rs3395132895 | 452 | H>R | No | EVA | |
| rs3388734063 | 469 | M>I | No | EVA | |
| rs3388734106 | 479 | P>A | No | EVA | |
| rs3388734091 | 486 | S>I | No | EVA | |
| rs3388737626 | 488 | V>I | No | EVA | |
| rs3388743297 | 540 | Q>H | No | EVA | |
| rs3388743271 | 563 | S>Y | No | EVA | |
| rs3388735057 | 611 | L>V | No | EVA | |
| rs3388738805 | 619 | Q>* | No | EVA |
No associated diseases with Q9JJP2
3 GO annotations of cellular component
| Name | Definition |
|---|---|
| chromatin | The ordered and organized complex of DNA, protein, and sometimes RNA, that forms the chromosome. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
6 GO annotations of molecular function
| Name | Definition |
|---|---|
| DNA binding | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). |
| DNA-binding transcription factor activity | A transcription regulator activity that modulates transcription of gene sets via selective and non-covalent binding to a specific double-stranded genomic DNA sequence (sometimes referred to as a motif) within a cis-regulatory region. Regulatory regions include promoters (proximal and distal) and enhancers. Genes are transcriptional units, and include bacterial operons. |
| DNA-binding transcription factor activity, RNA polymerase II-specific | A DNA-binding transcription factor activity that modulates the transcription of specific gene sets transcribed by RNA polymerase II. |
| metal ion binding | Binding to a metal ion. |
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II. |
| sequence-specific DNA binding | Binding to DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding. |
26 GO annotations of biological process
| Name | Definition |
|---|---|
| cell cycle | The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division. |
| cerebrospinal fluid secretion | The regulated release of cerebrospinal fluid (CSF) from the choroid plexus of the lateral, third and fourth ventricles. The cerebrospinal fluid is a clear liquid that located within the ventricles, spinal canal, and subarachnoid spaces. |
| digestive tract morphogenesis | The process in which the anatomical structures of the digestive tract are generated and organized. The digestive tract is the anatomical structure through which food passes and is processed. |
| DNA damage response | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism. |
| forebrain development | The process whose specific outcome is the progression of the forebrain over time, from its formation to the mature structure. The forebrain is the anterior of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes especially the cerebral hemispheres, the thalamus, and the hypothalamus and especially in higher vertebrates is the main control center for sensory and associative information processing, visceral functions, and voluntary motor functions). |
| hippocampus development | The progression of the hippocampus over time from its initial formation until its mature state. |
| inflammatory response | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. |
| intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage, and ends when the execution phase of apoptosis is triggered. |
| negative regulation of cardiac muscle cell proliferation | Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle cell proliferation. |
| negative regulation of neuron apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process in neurons. |
| negative regulation of neuron differentiation | Any process that stops, prevents, or reduces the frequency, rate or extent of neuron differentiation. |
| neuron development | The process whose specific outcome is the progression of a neuron over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. |
| positive regulation of apoptotic process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. |
| positive regulation of apoptotic signaling pathway | Any process that activates or increases the frequency, rate or extent of apoptotic signaling pathway. |
| positive regulation of cell size | Any process that increases cell size. |
| positive regulation of DNA-templated transcription | Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription. |
| positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator. |
| positive regulation of MAPK cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade. |
| positive regulation of oligodendrocyte differentiation | Any process that activates or increases the frequency, rate or extent of oligodendrocyte differentiation. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| post-embryonic development | The process whose specific outcome is the progression of the organism over time, from the completion of embryonic development to the mature structure. See embryonic development. |
| protein tetramerization | The formation of a protein tetramer, a macromolecular structure consisting of four noncovalently associated identical or nonidentical subunits. |
| regulation of gene expression | Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| regulation of mitotic cell cycle | Any process that modulates the rate or extent of progress through the mitotic cell cycle. |
| regulation of neuron apoptotic process | Any process that modulates the occurrence or rate of cell death by apoptotic process in neurons. |
| regulation of transcription by RNA polymerase II | Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II. |
4 homologous proteins in AiPD
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAQTSSSSSS | TFEHLWSSLE | PDSTYFDLPQ | PSQGTSEASG | SEESNMDVFH | LQGMAQFNLL |
| 70 | 80 | 90 | 100 | 110 | 120 |
| SSAMDQMGSR | AAPASPYTPE | HAASAPTHSP | YAQPSSTFDT | MSPAPVIPSN | TDYPGPHHFE |
| 130 | 140 | 150 | 160 | 170 | 180 |
| VTFQQSSTAK | SATWTYSPLL | KKLYCQIAKT | CPIQIKVSTP | PPPGTAIRAM | PVYKKAEHVT |
| 190 | 200 | 210 | 220 | 230 | 240 |
| DIVKRCPNHE | LGRDFNEGQS | APASHLIRVE | GNNLAQYVDD | PVTGRQSVVV | PYEPPQVGTE |
| 250 | 260 | 270 | 280 | 290 | 300 |
| FTTILYNFMC | NSSCVGGMNR | RPILVIITLE | TRDGQVLGRR | SFEGRICACP | GRDRKADEDH |
| 310 | 320 | 330 | 340 | 350 | 360 |
| YREQQALNES | TTKNGAASKR | AFKQSPPAIP | ALGTNVKKRR | HGDEDMFYMH | VRGRENFEIL |
| 370 | 380 | 390 | 400 | 410 | 420 |
| MKVKESLELM | ELVPQPLVDS | YRQQQQQQLL | QRPSHLQPPS | YGPVLSPMNK | VHGGVNKLPS |
| 430 | 440 | 450 | 460 | 470 | 480 |
| VNQLVGQPPP | HSSAAGPNLG | PMGSGMLNSH | GHSMPANGEM | NGGHSSQTMV | SGSHCTPPPP |
| 490 | 500 | 510 | 520 | 530 | 540 |
| YHADPSLVSF | LTGLGCPNCI | ECFTSQGLQS | IYHLQNLTIE | DLGALKVPDQ | YRMTIWRGLQ |
| 550 | 560 | 570 | 580 | 590 | 600 |
| DLKQSHDCGQ | QLLRSSSNAA | TISIGGSGEL | QRQRVMEAVH | FRVRHTITIP | NRGGAGAVTG |
| 610 | 620 | 630 | |||
| PDEWADFGFD | LPDCKSRKQP | IKEEFTETES | H |